NASDAQ:GLUE Monte Rosa Therapeutics Q1 2025 Earnings Report $5.94 +0.04 (+0.68%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$5.94 0.00 (0.00%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Monte Rosa Therapeutics EPS ResultsActual EPS$0.57Consensus EPS -$0.24Beat/MissBeat by +$0.81One Year Ago EPSN/AMonte Rosa Therapeutics Revenue ResultsActual Revenue$84.93 millionExpected Revenue$13.57 millionBeat/MissBeat by +$71.36 millionYoY Revenue GrowthN/AMonte Rosa Therapeutics Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time7:00AM ETUpcoming EarningsMonte Rosa Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Monte Rosa Therapeutics Earnings HeadlinesMonte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader MedicinesJuly 3, 2025 | globenewswire.comMonte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory DiseasesJune 10, 2025 | globenewswire.comMissed the Last 10,000% Surge? Here’s Your Next ChanceWe’ve uncovered small-cap stocks that have delivered big wins—before the rest of the market caught on. We don’t rely on luck—we rely on data, trends, and research. Our team is constantly scanning the market to spot hidden opportunities before they explode. What if you could get alerts on high-potential companies—before the crowd? | Fierce Investor (Ad)Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comMonte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business UpdatesMay 8, 2025 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast CancerApril 28, 2025 | globenewswire.comSee More Monte Rosa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Monte Rosa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monte Rosa Therapeutics and other key companies, straight to your email. Email Address About Monte Rosa TherapeuticsMonte Rosa Therapeutics (NASDAQ:GLUE) (NASDAQ:GLUE) is a biotechnology company focused on the discovery and development of small-molecule therapies that harness targeted protein degradation to treat a broad range of diseases. The company’s approach centers on molecular glues and bifunctional degraders, which recruit the cell’s natural protein disposal machinery to selectively eliminate disease-causing proteins. Monte Rosa’s lead research areas include oncology and immunology, with a pipeline of discovery-stage programs designed to address both solid tumors and hematologic malignancies. At the core of Monte Rosa’s efforts is a proprietary platform that integrates computational biology, chemoproteomics and medicinal chemistry. This platform allows rapid identification of novel degrader candidates and optimization of their pharmacologic properties. By combining high-throughput screening with machine learning algorithms, the company accelerates the translation of early-stage hits into development candidates, enabling a more efficient path to the clinic. Since its founding in 2019, Monte Rosa has established collaborations and research partnerships with leading pharmaceutical and academic institutions to expand its target space and validate degrader modalities. The company’s research facilities are headquartered in Cambridge, Massachusetts, and it maintains a strategic research presence in the United Kingdom to leverage regional expertise and foster transatlantic scientific exchange. Monte Rosa is led by a seasoned team of executives and scientific leaders with decades of experience in drug discovery, translational research and clinical development. The senior leadership includes professionals who have held key roles in both emerging biotech firms and established pharmaceutical companies, guiding the organization’s strategic vision and advancing its mission to develop transformative therapies for patients with unmet medical needs.Written by Jeffrey Neal JohnsonView Monte Rosa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)America Movil (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
